Endevica Bio Unveils Differentiated Mechanism for Durable Weight Loss in Obesity

NORTHBROOK, Ill., Oct. 2, 2025 /PRNewswire/ -- Endevica Bio, a clinical-stage biotechnology company pioneering peptide therapeutics for metabolic diseases, announced a major scientific breakthrough that could redefine the therapeutic landscape for general obesity treatment. The company's research demonstrates that co-agonism of the melanocortin-3 and melanocortin-4 receptors (MC3/4R) drives robust weight loss, unlocking the melanocortin system as a differentiated mechanism of action to complement and rival current obesity treatments.

GLP-1 receptor agonists dominate today's obesity market, despite several drawbacks. Gastrointestinal side effects drive high discontinuation rates, and patients commonly experience significant weight regain after stopping treatment. Additionally, GLP-1–induced weight loss includes lean mass loss, raising concerns about long-term health outcomes. Obesity is a complex disease that requires differentiated therapeutic approaches to address the needs of a diverse patient population.

For decades, MC4R has been recognized as a key target for obesity. Despite its promise, MC4R-selective approaches have failed to deliver meaningful weight loss in individuals with general obesity. Endevica Bio now demonstrates that dual activation of MC3R and MC4R may be the key to unlocking superior weight loss efficacy compared to MC4R agonism alone.

Endevica Bio's orally available, dual-MC3/4R agonist 710GO demonstrates the following in obese nonhuman primates:

• 11.7% reduction in body weight over 15 weeks as a monotherapy
• Minimal weight rebound of 1.1% at 7 weeks following cessation of treatment
• No gastrointestinal side effects, including diarrhea or vomiting
• Greater proportion of fat mass loss relative to lean mass loss, compared to GLP-1s

Beyond functioning as a standalone treatment, MC3/4R co-agonism offers a powerful synergistic mechanism to existing drug classes, including GLP-1 receptor agonists and amylin analogs. Data show that combining Endevica Bio's 710GO with incretins unlocks additive effects, further enhancing weight loss while potentially mitigating incretin-associated side effects.

"Our findings fundamentally change how we think about melanocortin biology in obesity," said Russell Potterfield, CEO of Endevica Bio. "For the first time, we have clear evidence that MC3R plays a pivotal and previously underappreciated role in regulating body weight in nonhuman primates. By harnessing the power of MC3/4R co-agonism, we're charting a new course in obesity treatment — one that goes beyond the limitations of MC4R-targeted therapies and GLP-1s."

The implications are far-reaching: Endevica Bio's novel approach has the potential to reshape the obesity market both as a monotherapy and in combinations offering next-generation treatment regimens. With a differentiated mechanism, oral dosing convenience, and robust efficacy, MC3/4R co-agonism represents one of the most promising new therapeutic strategies in the global fight against obesity.

About 710GO
710GO is an orally bioavailable peptide agonist with potent activity on the melanocortin-3 and melanocortin-4 receptors. It demonstrates preclinical weight loss efficacy in obese nonhuman primates without producing any adverse gastrointestinal effects. Notably, minimal rebound weight gain is observed after cessation of treatment with 710GO.

About Endevica Bio
Endevica Bio is a clinical-stage biotechnology company focused on developing transformative therapies for metabolic and neuroendocrine diseases. Leveraging deep expertise in melanocortin biology and receptor pharmacology, Endevica is pioneering first-in-class treatments that address the underlying mechanisms of obesity and related metabolic disorders.

For more information, visit www.endevicabio.com

Media Contact:
[email protected]

SOURCE Endevica Bio